The solitary pulmonary nodule represents a common diagnostic challenge for clinicians. While most are benign, a significant number represent early, potentially curable lung cancers. With the increased utilisation of chest computed tomography, solitary pulmonary nodules are increasingly being identified and with lung cancer screening programmes now on the horizon globally, it is crucial clinicians are familiar with the evaluation and management of solitary pulmonary nodules. Through the evaluation of patient risk factors combined with computed tomography characteristics of solitary pulmonary nodules, including size, growth rate, margin characteristics, calcification, density and location; a clinician can assess the risk of malignancy. This article provides an up to date review of the imaging features of both benign and malignant solitary pulmonary nodules to assist in the identification of nodules that require histological confirmation or ongoing surveillance. In addition, we summarise the newly updated Fleischner Society Guidelines that provide clinicians with a framework for the evaluation and management of solitary pulmonary nodules.
Introduction
The identification of pulmonary nodules is increasingly common in Australia and worldwide with the increased utilisation of computed tomography (CT). A pulmonary nodule is defined as a rounded opacity, well or poorly defined, measuring up to 3 cm in maximal diameter and is surrounded completely by aerated lung. 1 A lesion larger than 3 cm is termed a pulmonary mass. 1 Solitary pulmonary nodules (SPN) are classified as solid or subsolid; the latter further divided into part-solid or ground glass nodules (GGN). GGN demonstrate opacification with a higher density than the surrounding tissues but not obscuring the underlying bronchovascular structures. 1 Part-solid nodules contain both solid and ground glass components. The differential diagnosis for a SPN remains broad, including neoplastic, inflammatory, infectious, congenital and vascular pathologies ( Table 1 ). The differential diagnoses of GGN differ from solid SPN and include benign processes such as focal inflammation, interstitial fibrosis and atypical adenomatous hyperplasia (premalignant) and malignant pathologies, including adenocarcinoma in situ, minimally invasive adenocarcinoma and invasive adenocarcinoma. 2 The prevalence of non-calcified SPN is 2-24% in the non-screening population and 17-53% in the screening population. 3 Most of these nodules are benign.
SPN are clinically important as they may represent an early, potentially curable malignancy, in particular, lung cancer, which is the leading cause of cancer death in Australia. 4 The prevalence of malignancy in patients with a SPN varies across studies ranging from 2 to 23%. 5, 6 It is important clinicians are familiar with the evaluation of SPN especially as the increased utilisation of CT has led to increased identification of incidental pulmonary nodules. The aim is to identify those nodules that represent early malignancy, while minimising the consequences of over investigation, including patient anxiety and cumulative radiation exposure. The malignant risk of a SPN can be assessed by considering a range of patient and radiological characteristics, which will be reviewed below. Several evaluation tools and guidelines have been developed to assist the clinician in assessing malignant risk and include the newly updated Fleischer Society Guidelines that are widely used throughout Australia.
Clinical evaluation Patient characteristics
Several patient characteristics have been identified as risk factors for pulmonary malignancy. These include increasing age, female sex, a current or prior history of smoking, a family history of lung cancer, a personal history of emphysema and fibrotic lung disease, previous malignancy (thoracic or extra-thoracic), previous asbestos, radium and uranium exposures. 7 Symptoms should also be considered. A thorough clinical history is a crucial first step in the evaluation of a SPN. Patient risk factors should be considered in association with the radiological characteristics to best stratify risk patients presenting with a SPN.
Pulmonary nodule characteristics
There is considerable overlap in radiological features between benign and malignant SPN; however, several predictive characteristics have been identified as aids for risk stratification. These include nodule size, volume doubling time (VDT), margin characteristics, calcifications, density and location.
Sub-solid nodules, which includes part-solid and pure GGN, should be evaluated separately as they can represent differing pathologies (Fig. 1) . Part-solid nodules have a higher risk of malignancy (odds ratio 1.4) in comparison with solid nodules. 7 While there are some inconsistencies, the largest published lung cancer screening dataset suggests pure GGN have the lowest risk of malignancy.
7 Sub-solid nodules are more likely to represent adenocarcinoma than other forms of primary lung malignancy. 9 CT chest is the recommended modality for assessment of SPN. 10 Initial CT should be contrast enhanced to exclude additional intra-thoracic abnormalities and subsequent surveillance CT scans should be non-contrast, thin section and ideally low radiation dose when follow up of a pulmonary nodule is the only indication for CT.
Size
Nodule size positively correlates to the risk of malignancy. 7, 11 Lesions >3 cm, termed pulmonary masses, have a high malignant risk and should be considered malignant until proven otherwise. Of nodules >10 mm, 15.2% are malignant and depending on nodule characteristics and patient risk factors many need upfront investigation rather than surveillance. 10, 11 Intermediate nodules 5-10 mm have a risk of malignancy of 1.3%.
11 SPN ≤ 5 mm have a risk of malignancy of <1%, even in high-risk patient groups. 3, 11 This is equivalent to the risk for patients without nodules. 11 An arbitrary threshold of ≥1% malignant risk is used to identify those nodules that require ongoing surveillance. 10 SPN nodules ≤ 5mm therefore do not routinely require surveillance as reflected in the Fleischer Society Guidelines. 10 
Margin characteristics
Malignant nodules are more likely to have irregular, lobulated or spiculated margins due to malignant cells spreading within the pulmonary interstitium ( Fig. 2A-C) . 12 Benign nodules are associated with smooth, rounded borders (Fig. 2D) . 12 There is however a significant overlap between groups with irregular margins also seen in inflammatory/infectious conditions and smooth rounded margins noted in~20% of primary lung cancers and most metastatic nodules. 12 
Calcification
Calcification can be seen in benign and malignant SPN. On non-contrast CT an attenuation value of >200 Hounsfield units (HU) is used to determine the presence of calcification. 13 Up to 6-10% of primary lung cancers demonstrate calcification on CT and certain metastatic malignancies including sarcomas typically show calcification. 14 The rate of calcification of carcinoid cancers is 8-35%.
14 Importantly, the patterns of calcification may be useful in determining whether a nodule is benign. Benign nodules typically demonstrate central, laminated and diffuse patterns of calcification, which may represent granulomas, as well as popcorn calcification that is pathognomonic for hamartomas ( Fig. 3A-D ).
14 Malignant nodules alternately, more commonly demonstrate punctate and eccentric patterns of calcification (Fig. 3E,F ). 14 
Density
Fat attenuation, −40 to −120 HU, is a characteristic feature for hamartomas (Fig. 4) . 16 Pulmonary hamartomas are benign neoplasms made up of cartilage, connective tissue, fat, muscle and bone. Up to 50% of pulmonary hamartomas demonstrate fat attenuation on initial CT. 16 Differentials for fat attenuation in a SPN include lipoid pneumonia or pulmonary metastases in liposarcoma or renal cell carcinoma.
Cavitation occurs in both benign and malignant conditions, including abscesses, infectious granulomas, vasculitis, pulmonary infarcts and primary and metastatic malignancies, classically squamous cell carcinoma (Fig. 5) . 13 Cavitary nodules with thin, smooth walls are typically benign, while, nodules with thick, irregular walls are more likely malignant. 13, 17, 18 In cavitary nodules with wall thickness <5 mm, 92% are benign. 17 In those with wall thickness >15 mm, 95% are malignant. 17 In intermediate nodules with wall thickness of 5-15 mm, 51% are benign and 49% malignant. 17 The air bronchogram sign described as an air-filled bronchus surrounded by airless lung is commonly seen in infectious consolidation. 19 However, within a SPN, air bronchograms are more commonly seen in malignant nodules. 20, 21 Air bronchograms in SPN are most commonly associated with adenocarcinomas and have been linked to the presence of an epidermal growth factor mutation in some studies.
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Location
The location of SNPs can help characterise the malignant risk. Upper lobe distribution is associated with an increased risk of malignancy with an odds ratio of 1.9. Specifically, the right upper lobe (RUL) has the highest rate of malignancy with 45% of all malignant nodules in one screening study localised to the RUL. 25 This is theorised to be a result of increased airflow into the RUL during initial inspiration and therefore increased exposure to inhaled carcinogens, especially in smokers. 25 Perifissural nodules, small solid nodules that on CT sit adjacent to the pleural fissure, predominately represent perifissural lymph nodes (Fig. 6) . These typically have a triangular or oval shape on axial views and a flat or lentiform configuration on coronal/sagittal views. 10 Nodules that fit the description of a perifissural lymph node are considered benign and do not require further imaging even if >6 mm. 7, 10 However, if a perifissural nodule shows high-risk features, such as a spiculated, irregular margin or distortion of the adjacent fissure, then surveillance imaging may be warranted.
Growth
Despite analysis of the above characteristics, some nodules remain indeterminate. In such cases, VDT, the time taken for the nodule to double its volume or to increase 26% in diameter is used as a measure for assessing growth of SPN and predicting benignity. 3 Previous imaging should be obtained wherever possible for a comparison of growth over time.
It has been proposed that computerised determination of volume rather than diameter measurement should be used for growth rate determination, especially in smaller nodules, as it is more sensitive in detecting growth. 27, 28 While some centres use computerised determination of volume, this is not universally available across Australia and many centres still use diameter as the measure of growth. In general, benign nodules typically grow very quickly or very slowly with a VDT of <30 days or >400 days respectively. 12 Malignant nodules typically have a VDT between 30 and 400 days. 12 The average VDT for lung cancer has been reported as 139 days. 29 The current consensus is that nodule growth stability at 2 years for solid nodules is representative of benignity of the nodule. This cut-off is supported by the recent NELSON screening trial, which demonstrated that <1% of malignant nodules fell outside this 2-year stability cut-off. 11 Notably, sub-solid nodules can represent slower growing malignant processes such as adenocarcinoma in situ and minimally invasive adenocarcinoma with VDTs of 457-813 days. 2 Because some sub-solid nodules may transform into a more aggressive phenotype, longer follow up of these patients should be considered.
Imaging modalities Computed tomography
CT chest is the recommended modality for assessment of SPN. Non-contrast enhanced CT chest should be used when pulmonary nodule surveillance is the only indication for imaging. CT images should be reconstructed with axial thin sections <1.5 mm and coronal and sagittal views to enable the accurate characterisation and measurement of pulmonary nodules. 10 Thick sections increase volume averaging, which affects characterisation of small nodules with respect to nodule density, calcification and part-solid morphologies.
Low-dose CT (<3 mGy) should be used whenever possible for subsequent surveillance scans to reduce cumulative patient radiation dose. 30 The American Association of Physicists in Medicine position statement notes that the epidemiological evidence of an increased risk of malignancy or mortality from radiation doses below 14 (E) Scattered punctate calcification seen in a malignant carcinoid tumour. 15 (F) Eccentric calcification in a primary lung adenocarcinoma.
14 100 mSv is inconclusive. 31 Notably, radiation doses used in routine medical imaging are much lower than 100mSv and therefore patient risk is likely to be very low. 31 
Positron emission technology
Positron emission technology (PET) is also used in the evaluation of SPN. 18-fluoro-2-deoxy-D-glucose (FDG)
is used to measure glucose metabolism to grade metabolic activity reported as the standardised uptake value (SUV). 12 Malignancies typically have high metabolic activity and therefore demonstrate increased uptake, trapping and accumulation of FDG and are termed PET avid. 12 PET/CT utilises CT imaging in addition to PET to enable more accurate localisation of an area of FDG uptake to the underlying anatomical structures. The main role for PET/CT is in the further characterisation of discordant SPN with low pre-test probability and indeterminate CT characteristics. 5 A secondary indication is in targeting biopsies to the most metabolically active and therefore highest yield region of a concerning nodule. 5 The sensitivity and specificity of FDG-PET/CT using a SUV >2.5 to identify malignant SPN is reported at 87-94.2 and 83% respectively. 5, 32 However, in nodules <8-10 mm in diameter it is less sensitive. 5 False negatives can be seen with bronchoalveolar carcinoma, carcinoid tumours and mucinous adenomas. 5 False positives are seen with inflammatory and infectious conditions, including, tuberculosis, rheumatoid nodules, sarcoidosis and endemic mycoses, among others. 5 
Malignant risk and risk models
Assessment of the patient and nodule characteristics discussed above can facilitate an estimation of the malignant risk of a SPN and should be performed prior to determining subsequent management. Clinicians may assess this risk qualitatively or use the assistance of Figure 4 Pulmonary hamartoma in a contrast-enhanced computed tomography (CT) scan demonstrating a well circumscribed nodule with low density attenuation (-46HU) consistent with fat. quantitative models. Several quantitative prediction calculators including the Bayesian, Veteran Affairs, Brock University, Mayo Clinic and Herder models have been established with varying accuracy and generalisability. 7, [33] [34] [35] [36] The Brock and Mayo models are summarised in Table 2 33 Notably, these risk calculators were formulated from very different patient cohorts and the populations in which the risk calculators were derived from were restricted by various exclusion criteria that may limit generalisability. In clinical practice, patients presenting with SPN will often fall outside these criteria, therefore the clinician should be aware of the limitations of these risk calculators in their patient cohort. There is no consensus as to what percentage equates to high risk; suggested figures range from 5 to 65% across guidelines. 10, 37 Discussion SPN are increasingly being identified and may pose apprehension to the clinician and patient. Effective methods to evaluate the malignant potential and identify SPN that require ongoing surveillance or definitive investigations are crucial to avoid late diagnosis of lung cancer. This needs to be balanced by the risk of overinvestigation, cumulative radiation exposure and patient anxiety. Several guidelines have been developed using the aforementioned patient and nodule-specific characteristics to assist the clinician in this decision-making process. These include the Fleischner Society guidelines (revised and updated in 2017), the British Thoracic Society (BTS) guidelines (released in 2015) and the American College of Chest Physicians (ACCP) guidelines (revised and updated in 2013). 10, 37, 38 All three guidelines provide an evidenced-based approach to incidentally detected SPN using patient and nodule risk factors in addition to nodule size to guide the clinician. SPN with clear benign features, including typical perifissural nodules, generally do not require follow up. Nodules without clear benign features are termed indeterminant and are first stratified by their composition (solid, part-solid, GGN), followed by size and then an assessment of the malignant risk, incorporating both nodule and patient factors.
In general, the Fleischner guidelines are similar to the BTS and ACCP guidelines; however, there are some notable differences. BTS places a higher emphasis on volumetry as well as VDT and additionally incorporates the risk calculators directly into the decision-making algorithm. Also, the minimum size threshold for follow up differs with ACCP using a diameter of 4 mm, BTS 5 mm or 80 mm 3 and Fleischner Society 6 or 100 mm 3 . Furthermore, the suggested follow-up intervals and total duration of surveillance varies between guidelines. Notably the Fleischner Society recommends a surveillance duration for sub-solid nodules of 5 years, while the BTS and ACCP recommend 4 and 3 years respectively. Importantly clinicians must consider the inclusion criteria of the guidelines to assess for generalisability to the patient of concern. Patients excluded from the Fleischner guidelines include patients aged <35 years, patients with known primary malignancies at risk for metastases and immunocompromised patients at risk of infections. The Fleischner guidelines do not pertain to lung cancer screening-detected nodules, while BTS guidelines include all SPN detected in adults aged ≥18 years, irrespective of the route of detection. The Fleischner Society is an international, multidisciplinary medical society and their guidelines are widely known and practised across Australia. They have combined their guidelines into one table, simplifying use for clinicians and have recommended a reduced number of unnecessary follow-up CT while providing greater discretion to the clinician and patient to make management decisions. Thus, a range of times rather than a specific interval for follow-up CT is given for many scenarios. This change has been made in recognition of the multiple factors that determine risk as well as the important role of patient preference for either more aggressive or more conservative management. A summary of the Fleischner Society recommendations for follow up and management of incidental SPN is provided in Table 3 .
According to the Fleischner guidelines, low risk SPN <6 mm (<100 mm 3 ) do not typically require ongoing surveillance as the risk of malignancy in this group is <1%. In high-risk SPN <6 mm (<100 mm 3 ) an optional CT at 12 months may be appropriate based on the individual clinical context. SPN ≥ 6 mm require ongoing monitoring with surveillance CT at recommended intervals based on size and risk factors (Table 2) . SPN > 8mm (>250 mm 3 ) with growth or suspicious morphology should be further interrogated with histological evaluation or PET-CT scan. Solid and sub-solid nodules should be evaluated separately. Follow up should be tailored to the patient and consider the probability of malignancy and nodule characteristics. Solid pulmonary nodules are recommended to be monitored for 2 years to confirm growth stability, while, sub-solid nodules may represent slower growing malignant processes and should be followed for 5 years. The latest Fleischner guidelines have also included nodule volume as an option for size and growth monitoring, recognising the findings of recent studies that demonstrate computerised determination of volume to be more reproducible than measurement of diameter, especially in smaller nodules. 39 SPN that show clear growth on serial CT scans have a high likelihood of malignancy and should be further evaluated by biopsy or surgical resection. Biopsy options include CT-guided transthoracic lung biopsy, radial probe endobronchial ultrasound biopsy and surgical excision. The biopsy method selected should consider nodule location, morphology and patient comorbidities. In general; growing GGN with suspicious features that are not amenable to biopsy can be referred for surgical resection. 
Conclusion
The incidental finding of a SPN is an increasingly common clinical challenge encountered by clinicians. With the rising use and availability of CT imaging and lung cancer screening programmes now commenced overseas, it is clear this will be a growing problem in the years to come. The majority of SPN are benign; however, a small proportion represents early, potentially curable lung cancer. It is crucial clinicians have a method for evaluating SPN and their risk of malignancy to avoid missing malignancy while avoiding the complications of over investigation. Patient risk factors and nodules characteristics including size, margins, growth, density, location and calcification should be assessed in combination to assess the overall malignant risk of a SPN. Solid and sub-solid nodules can represent very different clinical processes and should be evaluated separately. Using the widely available risk calculators a clinician can calculate the overall risk of malignancy. We stress the importance of focusing on the clinical aspects of nodule characterisation when assessing the malignant risk of a SPN using a risk calculator. When evaluating a SPN previous imaging should be sought in the first instance and low dose CT used for surveillance whenever possible to reduce cumulative radiation exposure. There are several clinical guidelines, including those published by the Fleischner Society, that provide clinicians with a framework for the subsequent evaluation and monitoring of SPN.
